Mayer U - Search Results

1

Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.

Kröger N, Zabelina T, Sonnenberg S, Krüger W, Renges H, Stute N, Finkenstein F, Mayer U, Holstein K, Fiedler W, Colberg H, Sonnen R, Kuse R, Braumann D, Metzner B, del Valle F, Erttmann R, Kabisch H, Zander AR. Kröger N, et al. Among authors: mayer u. Bone Marrow Transplant. 2000 Oct;26(7):711-6. doi: 10.1038/sj.bmt.1702598. Bone Marrow Transplant. 2000. PMID: 11042650

2

Leukemic nodules at the site of G-CSF injection in acute myelomonocytic leukemia.

Dührsen U, Renges HH, Mayer U, Hossfeld DK. Dührsen U, et al. Among authors: mayer u. Eur J Haematol. 1995 Jan;54(1):51-2. doi: 10.1111/j.1600-0609.1995.tb01626.x. Eur J Haematol. 1995. PMID: 7532140 No abstract available.

3

Toxicity, pharmacokinetics and metabolism of iododoxorubicin in cancer patients.

Mross K, Mayer U, Langenbuch T, Hamm K, Burk K, Hossfeld D. Mross K, et al. Among authors: mayer u. Eur J Cancer. 1990;26(11-12):1156-62. doi: 10.1016/0277-5379(90)90276-y. Eur J Cancer. 1990. PMID: 2149998

4

Pharmacodynamic and pharmacokinetic aspects of iodo-doxorubicin.

Mross K, Mayer U, Zeller W, Becker K, Hossfeld DK. Mross K, et al. Among authors: mayer u. Oncol Res. 1992;4(6):227-31. Oncol Res. 1992. PMID: 1421615 Clinical Trial.

5

Pharmacokinetics and metabolism of iodo-doxorubicin and doxorubicin in humans.

Mross K, Mayer U, Hamm K, Burk K, Hossfeld DK. Mross K, et al. Among authors: mayer u. Eur J Clin Pharmacol. 1990;39(5):507-13. doi: 10.1007/BF00280945. Eur J Clin Pharmacol. 1990. PMID: 2076745

6

High-performance liquid chromatography of iodo-doxorubicin and fluorescent metabolites in plasma samples.

Mross K, Mayer U, Hamm K, Hossfeld DK. Mross K, et al. Among authors: mayer u. J Chromatogr. 1990 Aug 24;530(1):192-9. doi: 10.1016/s0378-4347(00)82321-x. J Chromatogr. 1990. PMID: 2277112 No abstract available.

7

Biliary transport of irinotecan and metabolites in normal and P-glycoprotein-deficient mice.

Iyer L, Ramírez J, Shepard DR, Bingham CM, Hossfeld DK, Ratain MJ, Mayer U. Iyer L, et al. Among authors: mayer u. Cancer Chemother Pharmacol. 2002 Apr;49(4):336-41. doi: 10.1007/s00280-001-0420-4. Epub 2002 Feb 1. Cancer Chemother Pharmacol. 2002. PMID: 11914914

8

Groth M, Henes FO, Mayer U, Regier M, Adam G, Begemann PG. Groth M, et al. Among authors: mayer u. Eur J Radiol. 2012 Aug;81(8):1913-6. doi: 10.1016/j.ejrad.2011.04.029. Epub 2011 May 5. Eur J Radiol. 2012. PMID: 21546178

9

Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr 1a P-glycoprotein.

Mayer U, Wagenaar E, Beijnen JH, Smit JW, Meijer DK, van Asperen J, Borst P, Schinkel AH. Mayer U, et al. Br J Pharmacol. 1996 Nov;119(5):1038-44. doi: 10.1111/j.1476-5381.1996.tb15775.x. Br J Pharmacol. 1996. PMID: 8922756 Free PMC article.

10

Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833.

Mayer U, Wagenaar E, Dorobek B, Beijnen JH, Borst P, Schinkel AH. Mayer U, et al. J Clin Invest. 1997 Nov 15;100(10):2430-6. doi: 10.1172/JCI119784. J Clin Invest. 1997. PMID: 9366556 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

325 results

Search Page

Filters